FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317470358> ?p ?o ?g. }

• W4317470358 endingPage "320" @default.
• W4317470358 startingPage "314" @default.
• W4317470358 abstract "Sinusoidal obstruction syndrome (SOS) is a potentially life-threatening complication that can be observed after allogeneic hematopoietic cell transplantation (HCT). Inotuzumab ozogamicin is an anti-CD22 monoclonal antibody-drug conjugate that has demonstrated high efficacy in relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) but is associated with an increased risk of SOS in HCT recipients. Here we aimed to examine the incidence and outcomes of SOS in 47 adult patients with R/R ALL who received inotuzumab therapy and subsequently underwent HCT at our institution. All patients received prophylactic therapy with ursodiol, and continuous low-dose heparin also was administered to patients receiving myeloablative conditioning (MAC). SOS occurred in 12 patients (26%) post-HCT, at a median onset of 11 days (range, 3 to 41 days). SOS was graded as very severe in 50% (n = 6), severe in 25% (n = 3), and mild in 25% (n = 3). All patients diagnosed with SOS received treatment with defibrotide for a median of 21 days (range, 3 to 34 days), with resolution of SOS occurring in 8 patients (67%). Mortality from SOS was 33% (n = 4) and occurred at a median of 10 days from diagnosis (range, 3 to 31 days) in patients graded as very severe (n = 3) or severe (n = 1). There were no significant differences between patients who developed SOS and those who did not develop SOS in the median time from the last dose of inotuzumab to transplantation (46 days versus 53 days; P = .37), use of an MAC regimen (42% versus 49%; P = .75), number of lines of therapy prior to inotuzumab (P = .79), median number of administered cycles of inotuzumab (2 versus 2; P = .14), or receipt of inotuzumab as the last therapy prior to HCT (67% versus 66%; P = 1.0). Sirolimus-based graft-versus-host disease (GVHD) prophylaxis was used more frequently in the SOS group (75% versus 29%; P < .01), but there was no between-group difference in the peak sirolimus level (P = .81) or the median time to peak sirolimus level (7 days versus 3.5 days; P = .39). In univariable analysis, only the use of sirolimus-based GVHD prophylaxis was significantly associated with an increased risk of SOS (hazard ratio [HR], 7.50; 95% confidence interval [CI], 1.7 to 33.6; P < .01). In the SOS group, the 100-day mortality rate was 33% (n = 4), and median overall survival (OS) post-HCT was 4.3 months (range, 0.2 to 57.2 months). In the group without SOS, the 100-day mortality rate was 14% (n = 5) and the median OS post-HCT was 10.7 months (range, .52 to 39.6 months). In this study cohort, SOS was prevalent in HCT recipients who had been treated with inotuzumab prior to transplantation, and sirolimus-based GVHD prophylaxis was a risk factor for SOS in inotuzumab recipients." @default.
• W4317470358 created "2023-01-20" @default.
• W4317470358 creator A5004337476 @default.
• W4317470358 creator A5015521146 @default.
• W4317470358 creator A5020684790 @default.
• W4317470358 creator A5024492683 @default.
• W4317470358 creator A5026632776 @default.
• W4317470358 creator A5038541414 @default.
• W4317470358 creator A5039374832 @default.
• W4317470358 creator A5040369089 @default.
• W4317470358 creator A5044575293 @default.
• W4317470358 creator A5048360588 @default.
• W4317470358 creator A5051018931 @default.
• W4317470358 creator A5052723726 @default.
• W4317470358 creator A5059382599 @default.
• W4317470358 creator A5060959458 @default.
• W4317470358 creator A5061899912 @default.
• W4317470358 creator A5063345064 @default.
• W4317470358 creator A5065052780 @default.
• W4317470358 creator A5066354077 @default.
• W4317470358 creator A5069640340 @default.
• W4317470358 creator A5070193149 @default.
• W4317470358 creator A5072317606 @default.
• W4317470358 creator A5072744089 @default.
• W4317470358 creator A5075695505 @default.
• W4317470358 creator A5078184054 @default.
• W4317470358 creator A5084027789 @default.
• W4317470358 creator A5086494836 @default.
• W4317470358 date "2023-05-01" @default.
• W4317470358 modified "2023-09-25" @default.
• W4317470358 title "Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab" @default.
• W4317470358 cites W1488000644 @default.
• W4317470358 cites W1779344217 @default.
• W4317470358 cites W1966771497 @default.
• W4317470358 cites W1973519172 @default.
• W4317470358 cites W1993783426 @default.
• W4317470358 cites W2027086946 @default.
• W4317470358 cites W2048623536 @default.
• W4317470358 cites W2048818389 @default.
• W4317470358 cites W2054025347 @default.
• W4317470358 cites W2055981604 @default.
• W4317470358 cites W2061293556 @default.
• W4317470358 cites W2079350855 @default.
• W4317470358 cites W2121599032 @default.
• W4317470358 cites W2151348405 @default.
• W4317470358 cites W2151475548 @default.
• W4317470358 cites W2295805773 @default.
• W4317470358 cites W2323586541 @default.
• W4317470358 cites W2396687607 @default.
• W4317470358 cites W2419639370 @default.
• W4317470358 cites W2591709377 @default.
• W4317470358 cites W2730231599 @default.
• W4317470358 cites W2782994300 @default.
• W4317470358 cites W2787301955 @default.
• W4317470358 cites W2809534462 @default.
• W4317470358 cites W2886906891 @default.
• W4317470358 cites W2917965199 @default.
• W4317470358 cites W2942381021 @default.
• W4317470358 cites W2969454127 @default.
• W4317470358 cites W2974201271 @default.
• W4317470358 cites W2977696805 @default.
• W4317470358 cites W3012219229 @default.
• W4317470358 cites W3038319750 @default.
• W4317470358 cites W3169193862 @default.
• W4317470358 cites W4282933337 @default.
• W4317470358 doi "https://doi.org/10.1016/j.jtct.2023.01.017" @default.
• W4317470358 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36682470" @default.
• W4317470358 hasPublicationYear "2023" @default.
• W4317470358 type Work @default.
• W4317470358 citedByCount "1" @default.
• W4317470358 countsByYear W43174703582023 @default.
• W4317470358 crossrefType "journal-article" @default.
• W4317470358 hasAuthorship W4317470358A5004337476 @default.
• W4317470358 hasAuthorship W4317470358A5015521146 @default.
• W4317470358 hasAuthorship W4317470358A5020684790 @default.
• W4317470358 hasAuthorship W4317470358A5024492683 @default.
• W4317470358 hasAuthorship W4317470358A5026632776 @default.
• W4317470358 hasAuthorship W4317470358A5038541414 @default.
• W4317470358 hasAuthorship W4317470358A5039374832 @default.
• W4317470358 hasAuthorship W4317470358A5040369089 @default.
• W4317470358 hasAuthorship W4317470358A5044575293 @default.
• W4317470358 hasAuthorship W4317470358A5048360588 @default.
• W4317470358 hasAuthorship W4317470358A5051018931 @default.
• W4317470358 hasAuthorship W4317470358A5052723726 @default.
• W4317470358 hasAuthorship W4317470358A5059382599 @default.
• W4317470358 hasAuthorship W4317470358A5060959458 @default.
• W4317470358 hasAuthorship W4317470358A5061899912 @default.
• W4317470358 hasAuthorship W4317470358A5063345064 @default.
• W4317470358 hasAuthorship W4317470358A5065052780 @default.
• W4317470358 hasAuthorship W4317470358A5066354077 @default.
• W4317470358 hasAuthorship W4317470358A5069640340 @default.
• W4317470358 hasAuthorship W4317470358A5070193149 @default.
• W4317470358 hasAuthorship W4317470358A5072317606 @default.
• W4317470358 hasAuthorship W4317470358A5072744089 @default.
• W4317470358 hasAuthorship W4317470358A5075695505 @default.
• W4317470358 hasAuthorship W4317470358A5078184054 @default.
• W4317470358 hasAuthorship W4317470358A5084027789 @default.
• W4317470358 hasAuthorship W4317470358A5086494836 @default.

• next